Business context and reporting period
Entity identification: The request names Novabridge Biosciences, but the supplied Form 20-F is for I-Mab (Nasdaq: IMAB), a Cayman Islands clinical-stage biopharmaceutical company. This summary follows the filing. It covers the fiscal year ended December 31, 2020—not a standalone fourth quarter—and presents U.S. GAAP results in RMB, with selected U.S. dollar equivalents.
I-Mab develops biologic drug candidates, principally for cancer and autoimmune diseases, through its China and Global portfolios. It had no approved products and generated no product-sales revenue in 2020; licensing and collaboration revenue was its principal source of revenue.
Key financial metrics
Amounts below are in RMB millions unless stated otherwise. Fiscal-year comparisons are 2020 versus 2019.
| Metric | 2020 | 2019 |
|---|---|---|
| Licensing and collaboration revenue | 1,542.7 | 30.0 |
| Research and development expense | 984.7 | 840.4 |
| Administrative expense | 402.4 | 654.6 |
| Income (loss) from operations | 155.6 | (1,465.0) |
| Net income (loss) attributable to I-Mab | 470.9 | (1,452.0) |
| Net income (loss) attributable to ordinary shareholders | 470.9 | (1,485.0) |
| Operating cash flow | 433.6 | (868.0) |
| Investing cash flow | (201.9) | 212.5 |
| Financing cash flow | 3,440.5 | 152.7 |
Revenue was approximately US$236.4 million; net income was US$72.2 million. Operating income was about 10.1% of revenue and net income about 30.5%, but both figures reflect substantial collaboration and other non-routine items. Gross margin is not meaningful for the reported results: the filing does not present a conventional cost-of-revenue measure.
At December 31, 2020, cash and cash equivalents were RMB4,758.8 million (US$729.3 million), with no restricted cash. Total current assets were RMB5,343.7 million and total current liabilities RMB576.1 million. Total liabilities were RMB706.6 million; there were no short-term borrowings outstanding at year-end. The company reported total assets of RMB6,333.8 million and shareholders’ equity of RMB5,627.1 million.
Material changes versus the prior comparable period
- Revenue rose from RMB30.0 million to RMB1,542.7 million, driven by the AbbVie collaboration. The company recognized RMB228.8 million of allocated consideration for the lemzoparlimab license and revenue for initial development services; the filing’s transaction-price estimate also included a second milestone whose collection was not reported by year-end.
- R&D expense increased 17.2% to RMB984.7 million. Employee benefit costs rose sharply, including increased share-based compensation; lower CRO and in-licensed patent fees partly offset this.
- Administrative expense fell to RMB402.4 million, mainly because share-based compensation was lower than in 2019, when large director-related awards and repurchases contributed to expense.
- The company swung from a RMB1,452.0 million net loss to RMB470.9 million net income. Beyond operating income, 2020 included RMB412.9 million of other income, principally a RMB407.6 million gain on the transfer of an interest in I-Mab Hangzhou, and a RMB108.6 million equity-method loss from that affiliate.
- Operating cash flow improved to RMB433.6 million, but included working-capital movements and large non-cash items. Financing inflows of RMB3,440.5 million primarily reflected the IPO and a private placement; cash and cash equivalents rose substantially from year-end 2019.
Outlook, management commentary, risks and unusual items
- Development outlook: Management expected to submit an NDA for felzartamab as a third-line multiple-myeloma treatment in Q4 2021, complete enrollment in its second-line registrational study by Q3 2021, and pursue a 2021 China trial combining felzartamab with lemzoparlimab. Eftansomatropin alfa’s China Phase 3 study was expected to support an NDA submission in late 2022; top-line data were expected in Q2 2023. These are forward-looking plans, not reported outcomes.
- Manufacturing and commercialization: The Hangzhou biologics facility was planned to begin construction in 2021, with pilot capacity targeted for 2022 and broader operations targeted by the end of 2023. Domestic investors committed US$120 million equivalent to the facility entity; construction timing, funding and capacity remain execution risks.
- Liquidity: Management said existing resources were expected to fund operations and capital requirements for at least 12 months. It also expected expenses to increase and anticipated needing substantial additional funding over time. Future financing could dilute shareholders or impose restrictive terms.
- COVID-19: Management reported some early delays to clinical-trial initiation and enrollment, but no material disruption to ongoing trials or supply chains as of the filing. It warned that future effects remained uncertain.
- Key business risks: All drug candidates remained investigational; clinical failure, regulatory delays, patient enrollment, manufacturing scale-up, reimbursement, competition, dependence on CROs and licensing partners, intellectual-property protection, China-related regulatory and currency restrictions, and potential financing needs could materially affect prospects.
- Unusual and non-cash items: 2020 included RMB526.2 million of share-based compensation across R&D, administration and the equity-method affiliate, the RMB407.6 million deconsolidation gain, and the RMB108.6 million affiliate loss. The company reported that its internal control over financial reporting was effective at year-end and that material weaknesses identified in 2019 had been remediated. Its auditor issued an unqualified opinion on the financial statements, but did not attest to internal-control effectiveness.
- Contingency: A dispute with Tracon over collaboration agreements remained unresolved. The company gave notice in February 2021 to terminate the TJD5 agreement, which would trigger a stated US$9.0 million termination fee.
Important facts for investors to verify
- Confirm the issuer identity: the filing is I-Mab, not Novabridge Biosciences, and the reported period is full-year 2020 rather than Q4 alone.
- Review the AbbVie agreement’s revenue recognition, milestone conditions, cash receipts, RMB130.5 million accounts receivable and RMB227.4 million contract assets; distinguish recognized revenue from cash collected.
- Separate recurring operating economics from the deconsolidation gain, affiliate loss and share-based compensation when assessing the reported profit and cash generation.
- Track clinical and regulatory milestones against the filing’s stated timelines, especially felzartamab’s NDA path and the progress and results of later-stage trials.
- Assess Hangzhou facility financing, construction progress, the affiliate’s economics, and the terms and potential obligations associated with the US$120 million investor commitment.
- Monitor cash use, future financing and dilution exposure, including outstanding warrants, equity awards and any additional capital needs.
- Follow the Tracon dispute and termination fee, as well as clinical, regulatory, manufacturing, intellectual-property and China-related risks.